CRISPR Field – Patent Fight Extended: Focus On Science, Time Frames, Risks – Seeking Alpha
R & D Magazine |
CRISPR Field – Patent Fight Extended: Focus On Science, Time Frames, Risks
Seeking Alpha Outside of venture capital meetings and scientific forums on the topic, the idea of CRISPR is poorly understood and looked at with a mix of concern and awe at what it may allow the scientific and medical community to do. In looking at the focus of … Researchers in US improve accuracy of CRISPR-Cas9 gene-editing toolXinhua |
Clinical Oncology News |
CAR T-Cell Therapy Roundup
Clinical Oncology News Chicago—The field of chimeric antigen receptor (CAR) therapy has been heating up, with the recent approval of Novartis’ CAR T-cell therapy tisagenlecleucel (Kymriah) for patients with acute lymphoblastic leukemia (ALL). Other CAR T-cell constructs are … |
Science Magazine |
Craig Venter’s synthetic biology company hit with gender discrimination suit
Science Magazine Oliver Fetzer, the CEO of Synthetic Genomics, which makes lab tools for synthetic biology, said in a statement emailed to reporters that the lawsuit is “without merit and we will vigorously defend the claims.” Fetzer added that like many life sciences … |
Medical Xpress |
Promising immunotherapy drug now available for some lung cancer patients in England
Medical Xpress Rose Gray, Cancer Research UK’s senior policy adviser, welcomed the decision to provide the promising drug, which is a kind of immunotherapy. NICE had previously said there was not enough evidence that nivolumab worked and that it was too expensive … Life-extending lung cancer drug will be made available on the NHSCambridge News Nivolumab to be made available to lung cancer patients in England and Wales, says NICEThe Pharmaceutical Journal |